Wells Fargo Report Says GLP-1s Reducing Certain Surgeries
Share
Robin Wenzel, head of Wells Fargo Industry Insights, said that the rise of GLP-1s has brought down the rate of bariatric surgery by more than 30%, providing a less invasive 'pharmaceutical offramp' for weight management. Wenzel said GLP-1 use rose 120% between 2022 and 2024 and that it offers the parts of the healthcare industry an opportunity to turn to helping patients manage medication or their side effects.
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access